I've been doing protein pharma research and the structure is only a first step, then years of figuring out the kinematics and dynamics of the protein, figuring out how it works, how all the natural ligands bind and affect the kinematics.. and only after all that you might conceivably start to engineer drug compounds (unless you bootstrap by a natural ligand to tweak "randomly", but then again, that's how pharma development traditionally works).
Still, even if structure determination is not on the "critical path", it IS a big barrier that has (started) to fall now.